I suppose this is to be expected for a company without a retail product undergoing an expensive R & D process with its lead candidate.
Opexa Therapeutics 4Q Loss Widens
Opexa Therapeutics' 4th-Quarter Loss Widens on Higher Research and Development Costs
March 18, 2008: 09:22 AM EST
NEW YORK (Associated Press) - Biotechnology company Opexa Therapeutics Inc. said Tuesday its 2007 loss widened on higher research and development expenses.
The company lost $14.7 million, or $2.19 per share, compared with a loss of $12.6 million or $2.35 per share. The company had no revenue in 2007 or 2006. Opexa had about 1.3 million additional shares in 2007.
Opexa did not report fourth-quarter results.
Research and development expenses rose 70 percent to about $13.1 million, primarily due to midstage studies of the company's experimental multiple sclerosis treatment Tovaxin.
More details can be found at this page